Scipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market

❮ Back to all posts

PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory.
Partnership provides infrastructure for rapid scaling and patient accessibility.

SEPTEMBER 17, 2020- WALTHAM, MA, and ALISO VIEJO, CA – Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced a strategic partnership with leading clinical genetic and genomic testing laboratory Ambry Genetics. Both parties began working together in early 2020 to build a robust sequencing process for PrismRA ensuring that the test can scale to provide rapid patient access. PrismRA®, a first-of-its-kind blood-based molecular signature test, accurately predicts inadequate response to tumor necrosis factor inhibitor (TNFi) therapies, the most widely prescribed targeted therapy for the estimated 20 million people living with rheumatoid arthritis (RA) globally.